Connor Clark & Lunn Investment Management Ltd. Raises Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Connor Clark & Lunn Investment Management Ltd. boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 88.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 147,236 shares of the biotechnology company's stock after buying an additional 68,992 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.15% of Sarepta Therapeutics worth $17,902,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its position in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after buying an additional 543,143 shares during the last quarter. Wellington Management Group LLP boosted its position in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Geode Capital Management LLC boosted its position in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Sarepta Therapeutics by 9.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company's stock worth $94,148,000 after purchasing an additional 63,437 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in Sarepta Therapeutics in the 3rd quarter worth approximately $79,425,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $98.37 on Friday. The stock has a market cap of $9.55 billion, a PE ratio of 78.70 and a beta of 0.79. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a twelve month low of $97.11 and a twelve month high of $173.25. The stock has a fifty day simple moving average of $112.83 and a 200-day simple moving average of $120.55.

Insider Activity at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Piper Sandler lowered their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Royal Bank of Canada decreased their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. HC Wainwright reiterated a "sell" rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $170.41.

Remove Ads

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.